You have full access to this article via your institution. Figure 2: Differential interaction of Apo2L trail versions with hepatocytes.

In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against other firms that posted double-digit gains on Thursday. Wall Street’s main indices finished in ...

The discovery that RIPK1 deficiency sensitizes the liver to acute injury and hepatocyte apoptosis is based on convincing evidence, highlighting the importance of RIPK1 in maintaining liver homeostasis ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared to its daily average volume of about 5.67 million. All thanks to three ...

Tempus AI (NASDAQ: TEM), a healthcare technology company, saw its stock surge 45% in a week after the company announced the launch of its AI app – Olivia. TEM stock was listed on June 14 ...

In this article, we are going to take a look at where Tempus AI (NASDAQ:TEM) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception. Markets have moved ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...